Report cover image

U.S. Sealing Membranes Market Size, Share, Trends, Analysis Report By Product Type (Sheet Membranes, Liquid-Applied Membranes), By End Use (Residential, Commercial, Industrial) – Market Forecast, 2025–2034

Published Sep 01, 2025
Length 126 Pages
SKU # PLRS20451515

Description

The U.S. sealing membranes market size is expected to reach USD 3.88 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Sealing Membranes Market Size, Share, Trends, Industry Analysis Report By Product Type (Sheet Membranes, Liquid-Applied Membranes), By End Use (Residential, Commercial, Industrial) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Sealing membranes, often described as protective layers engineered to safeguard structures against water ingress and vapor transmission, are evolving in line with emerging construction practices. The growing demand for eco-friendly and sustainable solutions drives the market growth. Increasing demand for low-VOC, recyclable, and nontoxic membranes reflects a broader focus on environmentally responsible construction practices. This trend is reinforced by the industry’s focus on long-term durability, energy efficiency, and alignment with green building certifications. Sealing membranes are no longer just protective barriers but also contributors to reducing environmental impact and enhancing building performance as sustainability becomes a central consideration.

The market is driven by the growing adoption of advanced material technologies that improve membrane efficiency and application flexibility. Continuous innovations have led to the development of membranes with superior resistance to moisture, chemicals, and temperature variations, offering longer service life and higher reliability. Advancements in self-adhesive systems and enhanced polymer formulations are also reducing installation time while ensuring consistent performance. These improvements support complex architectural requirements and also enhance the value proposition of sealing membranes. The role of advanced material technology is set to remain a cornerstone in the evolution of sealing membrane solutions, with innovation driving both functionality and convenience.

U.S. Sealing Membranes Market Report Highlights

Based on product type, the liquid-applied membranes segment dominated the market in 2024, favored for their versatility, ease of application, and cost-effectiveness in new construction and repairs.

In terms of end use, the commercial segment is poised for significant growth, fueled by rapid urbanization, commercial real estate expansion, and increased infrastructure investment.

A few key market players are AVM Industries, Carlisle SynTec Systems, DuPont, GAF Materials LLC, Johns Manville, Polyglass U.S.A., RPM International Inc., Sika Corporation, SOPREMA USA, and Tremco.

Polaris Market Research has segmented the U.S. sealing membranes market report based on product type and end use:

By Product Type (Revenue – USD Billion, 2020–2034)

Sheet Membranes

Liquid-Applied Membranes

By End Use (Revenue – USD Billion, 2020–2034)

Residential

Commercial

Industrial

Table of Contents

126 Pages
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Source
3.2.1. Primary Source
3.2.2. Secondary Source
4. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Insights
4.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Market Snapshot
4.2. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rising Expenditure on Animal Health
4.2.1.2. Increasing Investment in Facility Expansion
4.2.2. Restraints and Challenges
4.2.2.1. Stringent Regulation
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Trends
4.6. Value Chain Analysis
5. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type
5.1. Key Findings
5.2. Introduction
5.2.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
5.3. In-House
5.3.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by In-House, by Region, 2020-2034 (USD Billion)
5.4. Contract Outsourcing
5.4.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Contract Outsourcing, by Region, 2020-2034 (USD Billion)
5.4.2. Contract Development
5.4.2.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Contract Development, by Region, 2020-2034 (USD Billion)
5.4.2.2. Preclinical Development
5.4.2.2.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Preclinical Development, by Region, 2020-2034 (USD Billion)
5.4.2.3. Clinical Development
5.4.2.3.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Clinical Development, by Region, 2020-2034 (USD Billion)
5.4.3. Contract Manufacturing
5.4.3.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Contract Manufacturing, by Region, 2020-2034 (USD Billion)
6. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type
6.1. Key Findings
6.2. Introduction
6.2.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
6.3. Chemical-based API
6.3.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Chemical-based API, by Region, 2020-2034 (USD Billion)
6.4. Biological API
6.4.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Biological API, by Region, 2020-2034 (USD Billion)
6.5. HPAPI
6.5.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by HPAPI, by Region, 2020-2034 (USD Billion)
7. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type
7.1. Key Findings
7.2. Introduction
7.2.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
7.3. Production Animals
7.3.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Production Animals, by Region, 2020-2034 (USD Billion)
7.4. Companion Animals
7.4.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Companion Animals, by Region, 2020-2034 (USD Billion)
8. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category
8.1. Key Findings
8.2. Introduction
8.2.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
8.3. Antiparasitics
8.3.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Antiparasitics, by Region, 2020-2034 (USD Billion)
8.4. Anti-infectives
8.4.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Anti-infectives, by Region, 2020-2034 (USD Billion)
8.5. NSAIDs
8.5.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by NSAIDs, by Region, 2020-2034 (USD Billion)
8.6. Others
8.6.1. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)
9. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Geography
9.1. Key Findings
9.2. Introduction
9.2.1. Veterinary Active Pharmaceutical Ingredients Manufacturing Market Assessment, By Geography, 2020-2034 (USD Billion)
9.3. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Europe
9.3.1. Europe: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.2. Europe: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.3. Europe: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.4. Europe: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
9.3.5. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – UK
9.3.5.1. UK: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.5.2. UK: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.5.3. UK: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.5.4. UK: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
9.3.6. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – France
9.3.6.1. France: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.6.2. France: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.6.3. France: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.6.4. France: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
9.3.7. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Germany
9.3.7.1. Germany: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.7.2. Germany: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.7.3. Germany: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.7.4. Germany: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
9.3.8. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Italy
9.3.8.1. Italy: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.8.2. Italy: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.8.3. Italy: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.8.4. Italy: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
9.3.9. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Spain
9.3.9.1. Spain: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.9.2. Spain: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.9.3. Spain: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.9.4. Spain: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
9.3.10. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Netherlands
9.3.10.1. Netherlands: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.10.2. Netherlands: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.10.3. Netherlands: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.10.4. Netherlands: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
9.3.11. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Russia
9.3.11.1. Russia: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.11.2. Russia: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.11.3. Russia: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.11.4. Russia: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
9.3.12. Veterinary Active Pharmaceutical Ingredients Manufacturing Market – Rest of Europe
9.3.12.1. Rest of Europe: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Service Type, 2020-2034 (USD Billion)
9.3.12.2. Rest of Europe: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Synthesis Type, 2020-2034 (USD Billion)
9.3.12.3. Rest of Europe: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Animal Type, 2020-2034 (USD Billion)
9.3.12.4. Rest of Europe: Veterinary Active Pharmaceutical Ingredients Manufacturing Market, by Therapeutic Category, 2020-2034 (USD Billion)
10. Competitive Landscape
10.1. Expansion and Acquisition Analysis
10.1.1. Expansion
10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
11.1. Bayer AG
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Benchmarking
11.1.4. Recent Development
11.2. Boehringer Ingelheim International GmbH.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Benchmarking
11.2.4. Recent Development
11.3. ECO Animal Health Group PLC
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Benchmarking
11.3.4. Recent Development
11.4. Elanco
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Benchmarking
11.4.4. Recent Development
11.5. EUROAPI
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Benchmarking
11.5.4. Recent Development
11.6. FIS - Fabbrica Italiana Sintetici S.p.A.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Benchmarking
11.6.4. Recent Development
11.7. Kempex Holland BV
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Benchmarking
11.7.4. Recent Development
11.8. MSD Animal Health
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Benchmarking
11.8.4. Recent Development
11.9. SUANFARMA S.A
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Benchmarking
11.9.4. Recent Development
11.10. Zoetis Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Benchmarking
11.10.4. Recent Development
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.